Jonathan C. Trent

University of Miami — United States

Medicine · Health Sciences

60h-index14.6kcitations481works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(235), Gastrointestinal Tumor Research and Treatment(180), Gastric Cancer Management and Outcomes(91), Vascular Tumors and Angiosarcomas(50), Gastrointestinal disorders and treatments(46)

Publications481 total

Tumor Genomics, Metastatic Patterns, and Prognosis in Leiomyosarcoma: A Single-Center Retrospective Cohort Study
Cancers·2025Open Access
Author response for "Exploring Treatments for Hepatic Epithelioid Hemangioendothelioma: A Subsegmental Bland Embolization Case Series With Review"
2025
969P Real-world study of larotrectinib in patients with TRK fusion solid tumours: Interim analysis of ON-TRK
Annals of Oncology·2025
2743TiP First-in-human (FIH) phase I/II study of ADCE-D01, a urokinase plasminogen activator receptor-associated protein (uPARAP)-targeted antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload, in patients with metastatic and/or unresectable soft tissue sarcoma (STS)
Annals of Oncology·2025
<scp>BCOR</scp>‐Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study
Genes Chromosomes and Cancer·2025Open Access
Exploring Treatments for Hepatic Epithelioid Hemangioendothelioma: A Subsegmental Bland Embolization Case Series With Review
Cancer Control·2025Open Access
Author response for "Exploring Treatments for Hepatic Epithelioid Hemangioendothelioma: A Subsegmental Bland Embolization Case Series With Review"
2025
DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas
Cancers·2025· 2 citedOpen Access
Figure 3 from Phase I Study of the Mutant &lt;i&gt;IDH1&lt;/i&gt; Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
2025Open Access
Supplementary Table S1 from Phase I Study of the Mutant &lt;i&gt;IDH1&lt;/i&gt; Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
2025Open Access
Data from Phase I Study of the Mutant &lt;i&gt;IDH1&lt;/i&gt; Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
2025Open Access
Supplemental Figure S2 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Supplementary Table S2 from Phase I Study of the Mutant &lt;i&gt;IDH1&lt;/i&gt; Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
2025Open Access
Supplemental Figure S4 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Supplemental Figure S1 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Figure 1 from Phase I Study of the Mutant &lt;i&gt;IDH1&lt;/i&gt; Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
2025Open Access
Data from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Supplemental Figure S3 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Supplementary Methods 1 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Figure 2 from Phase I Study of the Mutant &lt;i&gt;IDH1&lt;/i&gt; Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
2025Open Access
page 1 of 25Next →

Frequent Co-authors

Robert S. Benjamin(13), Shreyaskumar Patel(11), Kelly K. Hunt(10), Raphael E. Pollock(9), Alexander J. Lazar(9), Margaret von Mehren(6), Suzanne George(6), Michael C. Heinrich(6), Peter W. T. Pisters(5), Lei L. Chen(5), Barry W. Feig(5), Haesun Choi(5), Robin L. Jones(5), Dejka M. Araujo(5), Filip Jankú(5), Yoon‐Koo Kang(4), William D. Tap(4), Piotr Rutkowski(4), Janice N. Cormier(4), Razelle Kurzrock(4)